The PTAB May Be Taking a More Balanced Approach in Biotech and Pharmaceutical IPRs | Bloomberg BNA

| Michael L. Fuller

Partner Michael Fuller wrote an article for the Bloomberg BNA - Pharmaceutical Law & Industry Report discussing how the PTAB may be taking a more balanced approach in biotech and pharmaceutical IPRs.

Reproduced with permission from Pharmaceutical Law & Industry Report, 13 PLIR 378, 03/13/2015. Copyright 2015 by The Bureau of National Affairs, Inc. (800-372-1033)